In November 2010, the iPrEx study reported that preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among heterosexual men and women. During regularly scheduled follow-up visits from January to March 2011, participants in an ongoing phase 2b vaccine efficacy trial completed an anonymous Web survey about PrEP. Among 376 respondents, 17% reported they were very likely to use PrEP in the next year. Nonwhite participants were more likely to use PrEP. Among those with some level of interest, intent to use PrEP was greatest if the drug were available through the clinical trial or health insurance. Most (91%) believed taking PrEP would not change their willingness to stay in the vaccine trial and few thought it would affect recruitment. As key stakeholders, currently enrolled trial participants can offer vital input about emerging prevention technologies that may affect the design of future HIV vaccine and nonvaccine prevention trials.
*San Francisco Department of Public Health, San Francisco, CA;
†Department of Medicine, University of California, San Francisco, CA;
‡Division of Infectious Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY;
§HIV Vaccine Trials Network;
‖Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA;
¶National Institutes of Allergy and Infectious Diseases, Bethesda, MD;
#Fenway Health and the Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; and
**Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY.
Correspondence to: Jonathan D. Fuchs, MD, MPH, San Francisco Department of Public Health, 25 Van Ness Avenue, Suite 100, San Francisco, CA 94102 (e-mail: firstname.lastname@example.org).
Preliminary analyses were presented at AIDS Vaccine 2011, Bangkok, Thailand.
The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases Grant AI068614AI068635, which supports T.M., D.G., S.K., M.A., and G.B.; J.F. is supported under a Division of AIDS CTU Award UO1AI069496; M.S. and S.H. are supported under CTU and CTSA Awards UO1AI69470 and UL1RR024156; K.M. is supported under CTU Awards UM1AI069480-05 and UO1AI069412 and unrestricted research grant support from Gilead Sciences, Inc; B.K. is supported under a CTU Award UO1AI69470.
HVTN 505 Protocol Team members and clinical research site investigators have been listed in Acknowledgments section.
The authors have no conflicts of interest to disclose.
Received January 02, 2013
Accepted March 22, 2013